This title appears in the Scientific Report :
2005
Please use the identifier:
http://dx.doi.org/10.1149/1.1905963 in citations.
Please use the identifier: http://hdl.handle.net/2128/2878 in citations.
On the nature of mixed potential in a DMFC
On the nature of mixed potential in a DMFC
This open-label extension evaluated the long-term efficacy and tolerability of rufinamide in patients with Lennox-Gastaut syndrome (LGS) who had previously completed a 12-week double-blind study.In total, 124 patients (aged 4-37 years), receiving 1-3 concomitant antiepileptic drugs, were treated wit...
Saved in:
Personal Name(s): | Kulikovsky, A. A. |
---|---|
Contributing Institute: |
Energieverfahrenstechnik; IWV-3 |
Published in: | Journal of the Electrochemical Society, 152 (2005) S. A1121 - A1127 |
Imprint: |
Pennington, NJ
Electrochemical Society
2005
|
Physical Description: |
A1121 - A1127 |
DOI: |
10.1149/1.1905963 |
Document Type: |
Journal Article |
Research Program: |
Brennstoffzelle |
Series Title: |
Journal of the Electrochemical Society
152 |
Subject (ZB): | |
Link: |
Get full text OpenAccess |
Publikationsportal JuSER |
Please use the identifier: http://hdl.handle.net/2128/2878 in citations.
This open-label extension evaluated the long-term efficacy and tolerability of rufinamide in patients with Lennox-Gastaut syndrome (LGS) who had previously completed a 12-week double-blind study.In total, 124 patients (aged 4-37 years), receiving 1-3 concomitant antiepileptic drugs, were treated with rufinamide approximately 25-60 mg/kg/day. Efficacy was assessed by seizure frequency; tolerability by adverse events (AEs) and laboratory tests.Overall, patients were treated with rufinamide for a median (range) of 432 (10-1149) days. Reductions in seizure frequency were observed throughout the study; during the last 12 months of treatment, 41.0% and 47.9% of patients had > or = 50% reduction in total and tonic-atonic seizure frequency, respectively. The most common AEs were vomiting (30.6%) and pyrexia (25.8%).In this open-label extension, rufinamide appeared to be an effective long-term adjunctive therapy for the treatment of LGS-associated seizures in children and young adults. |